$5.85
0.26%
Nasdaq, Oct 23, 03:58 pm EDT. Closed.
ISIN
US4037831033
Symbol
GYRE

Gyre Therapeutics Inc Stock price

$5.85
-1.55 20.95% 1M
-1.59 21.37% 6M
-1.21 17.14% YTD
-2.38 28.92% 1Y
-1.14 16.31% 3Y
+1.68 40.14% 5Y
-9.90 62.85% 10Y
-1,513.58 99.62% 20Y
Nasdaq, Closing price Fri, Oct 23 2026
-0.01 0.17%
ISIN
US4037831033
Symbol
GYRE
Industry

AI Insights on Gyre Therapeutics Inc Insights AI Insights on Gyre Therapeutics Inc

How does the company make money?
Who are the company’s main competitors?

Is Gyre Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,102 stocks worldwide.

Key metrics

Basic
Market capitalization
$620.3m
Enterprise Value
$545.5m
Net debt
positive
Cash
$74.8m
Shares outstanding
106.0m
Valuation
P/E
negative
P/S | estimate
5.2 | 5.6
EV/Sales | estimate
4.6 | 4.9
EV/FCF | ex SBC
negative | negative
P/B
4.8
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials
Revenue | estimate
$119.4m | $111.7m
EBITDA
$-10.2m
EBIT
$-13.6m
Net Income
$-18.5m
Free Cash Flow | ex SBC
$-16.8m | $-27.2m
Growth
Revenue | estimate
16.8% | -4.2%
EBITDA
-189.4%
EBIT
-246.8%
Net Income
-542.9%
Free Cash Flow
-942.9%
Margin
Gross
94.3%
EBITDA
-8.5%
EBIT
-11.4%
Net
-15.5%
Free Cash Flow | ex SBC
-14.1% | -22.8%
Financial Health
Equity Ratio
63.8%
Return on Equity
4.7%
ROCE
-8.0%
ROIC
-14.7%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$10.4m | 8.7%
SBC as % of FCF
-
SBC Growth 1Y
370.6%
Share Count Growth 1Y
16.7%
Shareholder Yield
-16.7%
More
EPS
$-0.2
FCF per Share
$-0.2
Short interest
6.5%
Employees
625
Rev per Employee
$190.0k

Gyre Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Gyre Therapeutics Inc forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Gyre Therapeutics Inc forecast:

Buy
89%
Hold
11%

Financial data from Gyre Therapeutics Inc

Jun '26
+/-
%
119 119
17% 17%
100%
- Direct Costs 6.81 6.81
63% 63%
6%
113 113
15% 15%
94%
- Selling and Administrative Expenses 93 93
23% 23%
78%
- Research and Development Expense 33 33
154% 154%
28%
-10 -10
189% 189%
-9%
- Depreciation and Amortization 3.46 3.46
66% 66%
3%
EBIT (Operating Income) EBIT -14 -14
247% 247%
-11%
Net Profit -18 -18
543% 543%
-15%

In millions USD.

Don't miss a Thing! We will send you all news about Gyre Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gyre Therapeutics Inc Stock News

Neutral
GlobeNewsWire
●
3 months ago
Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China's CDE in May 2026 SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical ...
Neutral
GlobeNewsWire
●
3 months ago
SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced that its Board of Directors has appointed three new members, effective August 1, 2026: Yue Xiong, Ph.D., the Company's Chief Scientific Officer...

Company Profile

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 618 full-time employees. The company went IPO on 2006-04-12. The company is also advancing a diverse pipeline in the PRC through its controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, and F528. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. The company is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. The company is also focused on commercializing the avatrombopag product and discovery and development of targeted protein degrader and degrader antibody conjugate therapies.

Head office United States
CEO Mr. Zhang
Employees 625
Website www.gyretx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today